Oncotype Dx (ODx)7–9 is a widely applied and extensively validated molecular assay in clinical practice with ODx score aiding in estimating the level of recurrence risk of ER+ and LN− IBC and treatment benefit from adjuvant chemotherapy. Here, ESR1 is linked to inflammatory breast carcinoma.